Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

You Call That An Offer? Facet Rejects Biogen's Hostile $355 Million Bid.

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Having twice said no and adopting a poison pill plan, the former R&D shop at PDL will stay independent--for now.

You may also be interested in...



Facet Cuts Shareholder Deals To Fight Off Hostile Biogen Bid

Biogen Idec will drop its $450 million tender offer, but the companies still must work together to develop two key drugs.

Facet Cuts Shareholder Deals To Fight Off Hostile Biogen Bid

Biogen Idec will drop its $450 million tender offer, but the companies still must work together to develop two key drugs.

Facet Rejects Biogen Again, Opens Up to Other Bids

The former R&D arm of biotech pioneer PDL waves off Biogen's $17.50-a-share offer, its third rejection since August.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS070074

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By